In agreement with our previous results (Figures 1, 2), these findings clearly demonstrated that the present newly-developed culture protocol (0.2% B27+NGF for 10–12 D.I.V.)really enriched with a good degree of homogeneity for a consistent, genuine and highly NGF-responsive population representing thus an useful tool for more specific in vitro assessment of the early AD-relevant, cholinergic-based processes associate with the loss in NGF/TrkA signaling. This evidence concerns the gene NGF and Alzheimer disease.